Related Experiment Video
Updated: Mar 25, 2026
06:19
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
2.1K
Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial
David T Rubin1, Marc Bradette2, Libor Gabalec3
1University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, USA.
Journal of Crohn'S & Colitis
|February 25, 2016
Summary
Maintenance therapy with multimatrix mesalazine effectively sustained remission in ulcerative colitis patients. Achieving complete remission before dose reduction significantly increased the likelihood of sustained remission at 12 months.
Area of Science:
- Gastroenterology
- Clinical pharmacology
Background:
- Assesses maintenance efficacy of multimatrix mesalazine in ulcerative colitis (UC).
- Evaluates treatment following induction with high-dose multimatrix mesalazine.
Purpose of the Study:
- To determine the effectiveness of multimatrix mesalazine maintenance therapy.
- To assess remission rates at 12 months post-induction in mild-to-moderate UC.
Main Methods:
- Phase 3b/4, open-label, multicentre, prospective, single-arm study.
- Induction: multimatrix mesalazine 4.8g/day for 8 weeks.
- Maintenance: multimatrix mesalazine 2.4g/day for 12 months in patients achieving remission.
Main Results:
- 25.9% complete remission and 39.3% partial remission at Week 8.
- At Month 12, 47.8% of patients in complete remission maintained it vs. 26.0% in partial remission (p < 0.001).
- Mucosal healing observed in 76.4% (complete remission) and 63.5% (partial remission) at Month 12.
Conclusions:
- Complete remission before dose reduction predicts higher likelihood of sustained remission.
- Multimatrix mesalazine maintenance therapy is effective in UC patients.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
605
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
605
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
657
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
657
01:21Inflammatory Bowel Disease V: Surgical Management
833
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
833
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
614
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
614
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
1.0K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.0K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
917
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
917